Summary

Calumet's March 13 8-K was a routine $150M bond add-on. Buried in the Purchase Agreement reps was the real signal: the DOE Loan Guarantee Agreement (dated Jan 10, 2025) confirmed as a live material agreement, warranted to institutional bond buyers under 10a liability. That's harder confirmation than any press release.

Cross-ticker corroboration elevated it. Montana Renewables' $1.44B DOE loan is the first Biden-era clean energy project to receive disbursement under Trump — $782M out the door while 80%+ of the $83.6B LPO portfolio gets restructured or killed. The equity co-sponsor is Warburg Pincus ($17.3B flagship fund, $250M preferred equity, board seat). Competitors are exiting SAF production. Insiders bought $3.9M coordinated on March 9th, six weeks before MaxSAF goes online.

The thesis is real. The price is not.

At $28.59, CLMT trades at 12.1x EV/EBITDA — a CCC+ credit priced like a growth story. The market already implies ≈$216M of forward EBITDA improvement, which is essentially a successful MaxSAF ramp at mid-case volumes. Probability-weighted EV: $18.74 base, $21.17 insider-adjusted. Both below current price.

The DOE Signal

The most important finding isn't in the cover filing. It's in Exhibit 1.1, lines 474-479 of the Purchase Agreement. Calumet's reps to institutional bond buyers explicitly reference the DOE Loan Guarantee Agreement and name the full party structure: Montana Renewables, DOE, Warburg Pincus (via WPGG 14 United Aggregator L.P.), and Citibank as program lender.

Why this matters: A company doesn't warrant a dead deal to bond investors under securities law. The 10a liability exposure makes this the strongest independent confirmation that the DOE loan is active. Not management commentary. Not a press release. A legal representation to sophisticated institutional buyers who did their own diligence.

The DOE angle got more interesting under cross-ticker corroboration. Montana Renewables received its $782M first tranche in February 2025 — while Trump's DOE was simultaneously killing $9.5B in wind/solar, de-obligating $29.9B, and restructuring $53.6B. Plug Power's comparable $1.66B DOE loan is frozen; they've suspended all DOE-related projects. Lithium Americas got restructured with DOE taking equity and a JV stake. Montana Renewables got cash.

Why? Sen. Daines (R-MT) personally lobbied the White House. Montana jobs, union workforce, agricultural feedstocks, energy security framing. This isn't wind and solar — it's biofuels in a red state with a GOP senator who wants the ribbon-cutting.

Second tranche (≈$658M) is the remaining risk. We put it at 55% by year-end.

The SAF Supply Thesis

The market frames CLMT as a renewable diesel play. It's wrong. The SAF-specific story is structurally different from RD.

Renewable diesel margins hit all-time troughs in Q4 2025 — management called it "the lowest renewable diesel index margin ever in the history of the world." Phillips 66 halted SAF production. Neste calls the US margin-dilutive. The RD market is brutal.

SAF is different. Airlines have committed billions of gallons they can't source: United 2.9B, Delta 910M, plus American, JetBlue, and others. US SAF production capacity grew 1,400% since 2024 but is still a fraction of commitments. Montana Renewables at full MaxSAF capacity would produce roughly 50% of North American SAF.

The premium is real and contracted. CLMT has 100M+ gallons under multiyear contracts at $1-2/gal premium over renewable diesel. The contracts are deliberately diversified: fixed-premium, scope 1/scope 3 credit sales, blended offtake, book-and-claim. Management designed the portfolio to perform across different regulatory scenarios.

World Energy offtake (70M gal/3yr), EPIC contract, Shell volume increase — these are signed contracts, not LOIs.

MaxSAF turnaround started mid-March. Online target: late April. First SAF revenue quarter: Q3 2026.

The Insider Signal

Five insiders bought $3.9M of CLMT stock on March 9th: CEO Borgmann ($1.43M), COO Fleming ($590K), SVP Obermeier ($689K), Director Mawer ($795K), General Counsel Morical ($439K). All acquisitions, same week, coordinated.

The timing is the tell. MaxSAF turnaround starts the following week. These people can see the construction schedule, the equipment readiness, the commissioning plan. They bought six weeks before the expected online date. Either they're reckless or they know something about where MaxSAF stands.

Options positioning confirms: near-term P/C ratio 0.22 (calls 4.5x puts), Jan 2027 call IV 8.8% above put IV. But there's a $5 strike put wall at Jan 2027 with 17,626 OI — someone big is long and hedged.

Factor Decomposition

250-day regression:

r_CLMT = 1.27*SPY + 0.49*XLB - 0.27*MTUM + e

SPY (market):     21.1% of variance
XLB (materials):   8.4%
MTUM (momentum):  -4.7%  (negative loading — contrarian name)
Idiosyncratic:    75.1%  (right at the Paleologo threshold)

Six economic factors drive the thesis. Three have edge, three don't:

Edge factors (≈52% of total variance):

• DOE Loan Guarantee — genuinely underpriced, evidence quality high (legal reps, first disbursement under Trump)
• MaxSAF Execution — insider signal suggests on-track, but mega-projects slip
• SAF Supply Position — 50% of NA SAF not consensus, contracted premium validated

No-edge factors (≈48% of total variance):

• RD Index Margins — macro/regulatory, all-time trough, RVO-dependent
• Credit/Refinancing — market access confirmed but $425M 2028 maturity looms
• Market Beta — 1.27x levered to SPY, pure beta exposure

The statistical decomposition says 75.1% idio. The economic decomposition says only 52-55% is edge-driven. The gap matters for sizing.

The three edge factors are positively correlated — DOE funds MaxSAF construction, MaxSAF produces SAF. If one fails, the others likely fail too. This creates a convex payoff: big up or big down. The 47.6% idio vol prices this correctly.

The Valuation Problem

Here's where the thesis dies at current price.

Enterprise Value:      $3.56B
FY2025 Adj EBITDA:     $293M
EV/EBITDA:             12.1x

Refining/specialty chemical comps trade at 5-8x. At a normalized 7x, the market implies $509M forward EBITDA — meaning $216M of MaxSAF improvement is already in the stock. That's roughly 100-130M gallons at $1.50-2.00/gal. The market is pricing the base case as a done deal.

Four scenarios, probability-weighted:

Probability-weighted EV: $18.74. Current price: $28.59.

The market prices 55% bull-or-better. We think 30%. The core disagreement: market believes MaxSAF execution is nearly certain. We think construction risk is real — 60% on-time, not 90%+.

Even crediting the insider buying signal fully (bumping MaxSAF to 80% on-time), the insider-adjusted EV is $21.17. Still 26% below current price.

Forward idio alpha at $28.59: approximately -51% annualized.

Entry Levels

Working backward from our EV:

A -35% pullback (to $18.50) is 0.7 sigma on 47.6% idio vol — well within normal range. Catalysts that could create the entry:

1. MaxSAF delay announcement (late April / May)
2. RVO disappointment or further delay
3. Broad market correction (beta 1.27 amplifies drawdowns)
4. Q1 earnings miss (May 8)
5. DOE political headline (Trump rhetoric against LPO)

Conclusion

Watchlist, not a position. The thesis has three genuine edges: DOE survival under a hostile administration (LR 2.5), coordinated insider buying ahead of MaxSAF (LR 2.2), and SAF supply positioning that the market misframes as an RD story (LR 1.8). All confirmed by primary sources.

But the stock is at the 88th percentile of its 52-week range, trading at 12.1x on a CCC+ credit. The market already prices a successful MaxSAF ramp. There's no alpha at $28.59 — we'd be buying confirmation, not discovery.

Set alerts at $18 and $15. When MaxSAF delays, or RVO disappoints, or the market sells off and beta drags this down 30%+, the thesis is identical but the math works.

One flag for the factor thesis: AMTX ($2.29, 89.6% idio) is a dramatically cheaper expression of the same DOE + SAF factors. Earlier stage, higher risk, but more asymmetry if the structural thesis is right. Worth a separate look.